133 related articles for article (PubMed ID: 12901280)
21. Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study.
Brugnatelli S; Danova M; De Bella MT; Vaglica M; Manuguerra G; Riccardi A; Palmeri S
Oncology; 2002; 62(1):33-8. PubMed ID: 11810041
[TBL] [Abstract][Full Text] [Related]
22. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
[TBL] [Abstract][Full Text] [Related]
23. Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor.
Kornek GV; Haider K; Kwasny W; Raderer M; Schüll B; Payrits T; Depisch D; Kovats E; Lang F; Scheithauer W
Clin Cancer Res; 2002 May; 8(5):1051-6. PubMed ID: 12006518
[TBL] [Abstract][Full Text] [Related]
24. Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study.
Fountzilas G; Nicolaides C; Bafaloukos D; Kalogera-Fountzila A; Kalofonos H; Samelis G; Aravantinos G; Pavlidis N
Cancer Invest; 2000; 18(6):503-9. PubMed ID: 10923097
[TBL] [Abstract][Full Text] [Related]
25. Docetaxel and ifosfamide in patients with advanced solid tumors: results of a phase I study.
Pronk LC; Schrijvers D; Schellens JH; de Bruijn EA; Planting AS; Locci-Tonelli D; Groult V; Verweij J; van Oosterom AT
Semin Oncol; 1998 Feb; 25(1 Suppl 2):23-8. PubMed ID: 9535208
[TBL] [Abstract][Full Text] [Related]
26. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group.
Mavroudis D; Malamos N; Alexopoulos A; Kourousis C; Agelaki S; Sarra E; Potamianou A; Kosmas C; Rigatos G; Giannakakis T; Kalbakis K; Apostolaki F; Vlachonicolis J; Kakolyris S; Samonis G; Georgoulias V
Ann Oncol; 1999 Feb; 10(2):211-5. PubMed ID: 10093691
[TBL] [Abstract][Full Text] [Related]
27. A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma.
Gitlitz BJ; Baker C; Chapman Y; Allen HJ; Bosserman LD; Patel R; Sanchez JD; Shapiro RM; Figlin RA
Cancer; 2003 Nov; 98(9):1863-9. PubMed ID: 14584068
[TBL] [Abstract][Full Text] [Related]
28. Docetaxel and gemcitabine combinations in non-small cell lung cancer.
Rizvi NA; Spiridonidis CH; Davis TH; Bhargava P; Marshall JL; Dahut W; Figuera M; Hawkins MJ
Semin Oncol; 1999 Oct; 26(5 Suppl 16):27-31; discussion 41-2. PubMed ID: 10585006
[TBL] [Abstract][Full Text] [Related]
29. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
Kakolyris S; Papadakis E; Tsiafaki X; Kalofonos C; Rapti A; Toubis M; Bania E; Kouroussis C; Chainis K; Androulakis N; Agelaki S; Sarra E; Vardakis N; Georgoulias V;
Lung Cancer; 2001 May; 32(2):179-87. PubMed ID: 11325489
[TBL] [Abstract][Full Text] [Related]
30. Phase I study of docetaxel and topotecan in patients with solid tumors.
Tkaczuk KH; Zamboni WC; Tait NS; Meisenberg BR; Doyle LA; Edelman MJ; Hausner PF; Egorin MJ; Van Echo DA
Cancer Chemother Pharmacol; 2000; 46(6):442-8. PubMed ID: 11138457
[TBL] [Abstract][Full Text] [Related]
31. Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer.
Bleickardt E; Argiris A; Rich R; Blum K; McKeon A; Tara H; Zelterman D; Burtness B; Davies MJ; Murren JR
Cancer Biol Ther; 2002; 1(6):646-51. PubMed ID: 12642688
[TBL] [Abstract][Full Text] [Related]
32. Docetaxel (Taxotere) and gemcitabine in the treatment of non-small cell lung cancer: preliminary results.
Georgoulias V; Kourousis C; Androulakis N; Kakolyris S; Dimopoulos MA; Bouros D; Papadimitriou C; Hatzakis K; Heras P; Kalbakis K; Kotsakis T; Vardakis N; Meramveliotakis N; Hatzidaki D
Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-22-S14-25. PubMed ID: 9335520
[TBL] [Abstract][Full Text] [Related]
33. A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
Amarantidis K; Houhouli K; Papatheodorou K; Miloussis A; Matthaios D; Chatzaki E; Lyrantzopoulos N; Tsaroucha A; Tentes A; Kakolyris S
Oncol Res; 2006; 16(6):281-7. PubMed ID: 17476973
[TBL] [Abstract][Full Text] [Related]
34. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.
Hainsworth JD; Burris HA; Erland JB; Thomas M; Greco FA
J Clin Oncol; 1998 Jun; 16(6):2164-8. PubMed ID: 9626217
[TBL] [Abstract][Full Text] [Related]
35. Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors.
Salazar R; Morales S; Gil-Martín M; Aguirre E; Oaknin A; Garcia M; Callies S; Wickremsinhe ER; Benhadji KA; Llombart A
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1205-15. PubMed ID: 24744161
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group.
Dreicer R; Manola J; Schneider DJ; Schwerkoske JF; George CS; Roth BJ; Wilding G;
Cancer; 2003 Jun; 97(11):2743-7. PubMed ID: 12767086
[TBL] [Abstract][Full Text] [Related]
37. Phase I study of paclitaxel and day 1/day 8 gemcitabine in patients with solid malignancies.
Fleming DR; Glisson SD; Bhupalam L; Michelson GD; Goldsmith GH; LaRocca RV
Am J Clin Oncol; 2000 Aug; 23(4):349-52. PubMed ID: 10955861
[TBL] [Abstract][Full Text] [Related]
38. A dose escalation study of weekly docetaxel in patients with advanced solid tumors.
Kouroussis C; Agelaki S; Mavroudis D; Souglakos J; Kakolyris S; Kalbakis K; Vardakis N; Reppa D; Hatzidaki D; Samonis G; Georgoulias V
Cancer Chemother Pharmacol; 2000; 46(6):488-92. PubMed ID: 11138462
[TBL] [Abstract][Full Text] [Related]
39. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma .
Sweeney CJ; Zhu J; Sandler AB; Schiller J; Belani CP; Langer C; Krook J; Harrington D; Johnson DH
Cancer; 2001 Nov; 92(10):2639-47. PubMed ID: 11745199
[TBL] [Abstract][Full Text] [Related]
40. Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors.
Rothenberg ML; Sharma A; Weiss GR; Villalona-Calero MA; Eckardt JR; Aylesworth C; Kraynak MA; Rinaldi DA; Rodriguez GI; Burris HA; Eckhardt SG; Stephens CD; Forral K; Nicol SJ; Von Hoff DD
Ann Oncol; 1998 Jul; 9(7):733-8. PubMed ID: 9739439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]